Stockscreener 앱 받기
26.94
3.02%
0.79
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
ACADIA Pharmaceuticals (ACAD) Sees Target Price Raised by Citigr - GuruFocus
UBS Raises Price Target to $40 for ACADIA Pharmaceuticals (ACAD) - GuruFocus
ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to "Hold" at Wall Street Zen - MarketBeat
What drives ACADIA Pharmaceuticals Inc stock priceMean Reversion Trades & Outstanding Wealth Building - earlytimes.in
ACADIA Pharmaceuticals Earnings Notes - Trefis
Insider Sell: Is ACADIA Pharmaceuticals Inc stock in correction or buying zoneIndex Update & Risk Controlled Swing Alerts - moha.gov.vn
(ACAD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Deutsche Bank Upgrades ACADIA Pharmaceuticals (ACAD) - MSN
Performance Recap: Can ACADIA Pharmaceuticals Inc stock hit analyst price targetsWeekly Earnings Recap & Verified Swing Trading Watchlists - moha.gov.vn
Rice Hall James & Associates LLC Sells 54,869 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals Inc. $ACAD Holdings Decreased by Assenagon Asset Management S.A. - MarketBeat
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? - AOL.com
Here's why Acadia Pharmaceuticals (ACAD) is a strong momentum stock - MSN
ACADIA Pharmaceuticals Advances Alzheimer’s Disease Psychosis Study with ACP-204 - MSN
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock - sharewise.com
Acadia Pharmaceuticals stock reaches 52-week high at $27.73 By Investing.com - Investing.com Nigeria
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year HighHere's Why - MarketBeat
Acadia Pharmaceuticals stock reaches 52-week high at $27.73 - Investing.com
Acadia Pharmaceuticals price target raised to $29 from $24 at Mizuho - MSN
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Its Strong 1-Year Share Price Rally - Yahoo Finance
Can ACADIA Pharmaceuticals Inc. stock maintain growth trajectoryWeekly Trading Summary & Reliable Breakout Stock Forecasts - Улправда
How ACADIA Pharmaceuticals Inc. stock compares to growth peers2025 EndofYear Setup & Weekly High Return Forecasts - ulpravda.ru
Market Recap: How ACADIA Pharmaceuticals Inc. stock compares to growth peersJuly 2025 Setups & Community Verified Trade Signals - Улправда
Is ACADIA Pharmaceuticals Inc. stock a defensive play in 2025Portfolio Update Summary & Fast Momentum Stock Entry Tips - Улправда
Can ACADIA Pharmaceuticals Inc. stock hit analyst price targets2025 Major Catalysts & Precise Buy Zone Identification - DonanımHaber
Will ACADIA Pharmaceuticals Inc. stock see PE expansionWeekly Trend Report & High Conviction Trade Alerts - DonanımHaber
Can ACADIA Pharmaceuticals Inc. stock attract ESG capital inflowsJuly 2025 Patterns & Real-Time Buy Signal Alerts - DonanımHaber
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 - Yahoo Finance
Is ACADIA Pharmaceuticals Inc. stock a good choice for value investorsQuarterly Portfolio Summary & Safe Capital Growth Trade Ideas - Улправда
What is HC Wainwright's Forecast for ACAD FY2028 Earnings? - MarketBeat
FDA approves Acadia’s Daybue Stix for Rett syndrome - MSN
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Stifel maintains ACADIA Pharmaceuticals (ACAD) hold recommendation - MSN
New DAYBUE STIX Rett Syndrome Formulation Might Change The Case For Investing In ACADIA Pharmaceuticals (ACAD) - simplywall.st
Acadia Pharmaceuticals stock price target raised to $37 by H.C. Wainwright - Investing.com
ACADIA Pharmaceuticals Inc. $ACAD Stock Position Trimmed by Hudson Bay Capital Management LP - MarketBeat
Neuren partner Acadia bags FDA go-ahead for new DAYBUE STIX powder for Rett Syndrome - Indian Pharma Post
ACAD Sees Boost in Price Target by HC Wainwright & Co. | ACAD St - GuruFocus
Neuren Pharmaceuticals’ partner Acadia gains FDA approval for new Rett syndrome treatment - MSN
FDA Approves Acadia Pharmaceuticals’ Daybue Stix for Treating Rett Syndrome - geneonline.com
FDA approves Acadia’s Daybue Stix for Rett syndrome treatment - Pharmaceutical Technology
Neuren Pharmaceuticals’ Partner Acadia Gains FDA Approval for New Rett Syndrome Treatment - TipRanks
Hohimer Wealth Management LLC Decreases Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
TFG Asset Management GP Ltd Has $3.48 Million Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Eventide Asset Management LLC Trims Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Birchview Capital LP Sells 75,600 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
FDA approves powder formulation of trofinetide for Rett syndrome - Contemporary Pediatrics
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (t - GuruFocus
2.52%
0.07%
자본화:
|
볼륨(24시간):